Plant Name: Alpinia galanga
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; | |
| TSHR; | |
| BCHE; ACHE; | |
| MAPK1; | |
| CA7; CA4; CA12; | |
| ALDH1A1; | |
| PTGS1; XDH; | |
| MAPT; GLI2; GLI1; LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | GLI2 | Zinc finger protein GLI2 | P10070 | CHEMBL5119 |
| Unclassified | GLI1 | Zinc finger protein GLI1 | P08151 | CHEMBL5461 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.282E-13 | 2.484E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.974E-12 | 4.336E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.546E-11 | 5.858E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.829E-11 | 5.858E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 5.118E-11 | 1.238E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, PTGS1 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.474E-10 | 4.143E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.080E-10 | 7.902E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.427E-09 | 4.016E-06 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.018E-09 | 7.855E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 3.865E-08 | 2.902E-05 | BCHE, CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.421E-07 | 1.551E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.997E-07 | 2.941E-04 | CA12, CA4, CA7 |
| BP | GO:0032502; developmental process | GO:0060032; notochord regression | 1.126E-06 | 6.128E-04 | GLI1, GLI2 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.126E-06 | 6.128E-04 | ACHE, BCHE |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.934E-06 | 9.794E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0032502; developmental process | GO:0007418; ventral midline development | 3.375E-06 | 1.531E-03 | GLI1, GLI2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 3.375E-06 | 1.531E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 5.140E-06 | 2.284E-03 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0023052; signaling | GO:0021938; smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation | 6.746E-06 | 2.880E-03 | GLI1, GLI2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.746E-06 | 2.880E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.727E-06 | 3.236E-03 | CA12, CA4, CA7 |
| BP | GO:0032502; developmental process | GO:0021696; cerebellar cortex morphogenesis | 1.124E-05 | 4.448E-03 | GLI1, GLI2 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.124E-05 | 4.448E-03 | CYP1A1, CYP3A4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.425E-05 | 5.542E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.684E-05 | 6.434E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 2.543E-05 | 9.387E-03 | ADORA3, BCHE, CYP1B1, GLI1, LMNA, MAPK1, PTGS1, TSHR, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.037E-10 | 2.322E-08 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 6.059E-09 | 3.453E-07 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.096E-08 | 4.164E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.097E-08 | 5.976E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.673E-07 | 8.373E-06 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 7.427E-07 | 1.210E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.182E-06 | 7.384E-05 | CYP2C9; MAPK1; CYP2C19; PTGS1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.086E-05 | 2.161E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; XDH; PTGS1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.614E-06 | 1.195E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.626E-05 | 3.444E-04 | CYP2C9; CYP2C19; PTGS1 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.720E-07 | 1.210E-05 | CA12; CA4; CA7 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.131E-03 | 8.891E-03 | MAPK1; GLI1; TSHR |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.248E-03 | 8.891E-03 | CYP1A1; CYP1B1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.057E-03 | 8.891E-03 | CYP3A4; XDH |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.563E-03 | 9.897E-03 | TSHR; PTGS1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 1.508E-03 | 9.897E-03 | GLI1; GLI2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 5.984E-03 | 3.590E-02 | ACHE; MAPK1 |
| hsa04340 | Hedgehog signaling pathway_Homo sapiens_hsa04340 | 1.248E-03 | 8.891E-03 | GLI1; GLI2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.916E-03 | 4.102E-02 | MAPK1; GLI1; GLI2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 7.184E-03 | 3.900E-02 | MAPK1; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 9.364E-03 | 4.641E-02 | LMNA; MAPK1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.959E-03 | 3.900E-02 | ADORA3; MAPK1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.048E-05 | 1.195E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; ADORA3; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Rheumatold arthritis | NA | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; ACHE; ACHE; ACHE |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | PTGS1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | PTGS1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |